Co-expression of Cancer Stem Cell Markers OCT4 and NANOG Predicts Poor Prognosis in Renal Cell Carcinomas

Rasti, Arezoo; Mehrazma, Mitra; Madjd, Zahra; Abolhasani, Maryam; Zanjani, Leili Saeednejad; Asgari, Mojgan

doi:10.1038/s41598-018-30168-4

Cited by 86 publications

(57 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Wang et al and Rasti et al reported an association between high Oct4 expression and poor prognosis and metastasis in hepatocellular and renal cell carcinomas, respectively [22,23]. On the other hand, Matsuoka et al suggested that Oct4 might repress the tumorigenic potential of GC cells.…”

Section: Discussionmentioning

confidence: 93%

Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival

El-Guindy

Wasfy

Ghafar

et al. 2019

J Egypt Natl Canc Inst

View full text Add to dashboard Cite

Background: Octamer-binding transcription factor 4 (Oct4) is a transcription factor that has an important role in stem cell differentiation and self-renewal. Oct4 has also been implicated in tumorigenicity of different cancers. This study aimed to analyze Oct4 expression in gastric carcinoma (GC) and to evaluate the relation between Oct4 expression and clinicopathologic parameters, tumor proliferation, and angiogenesis in addition to patient survival. Results: Oct4 mRNA was detected by quantitative reverse transcription PCR (qRT-PCR) in 45 GC specimens and adjacent non-cancerous tissues. We found a significant difference in Oct4 mRNA relative expression levels in GC tissue compared with adjacent non-cancerous tissues (p < 0.001). Furthermore, immunohistochemistry (IHC) was performed to study the Oct4 expression in GC cases. High Oct4 immunostaining was detected in 62.2% of GC specimens. High Oct4 expression both by mRNA relative quantitation and IHC were significantly related to poorly differentiated tumors, nodal metastasis, and stage III tumors. Moreover, high Oct4 IHC expression was also associated with cases positive for Ki-67 and VEGF expressions (p < 0.001 and 0.021, respectively). Oct4 expression identified by both mRNA relative quantitation and IHC was significantly related (p < 0.001). As regards patient survival, high Oct4 expression was significantly related to poor overall survival (OS) and disease-free survival (DFS) (p = 0.029 and 0.031, respectively). Conclusion: Oct4 plays a valuable role in the progression and prognosis of GC. High Oct4 expression is associated with high tumor grade, nodal metastasis, stage III tumors, and poor OS and DFS. High Oct4 is also significantly associated with Ki-67 and VGEF expression, thus enhancing tumor proliferation and angiogenesis.

show abstract

Section: Discussionmentioning

confidence: 93%

Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival

El-Guindy

Wasfy

Ghafar

et al. 2019

J Egypt Natl Canc Inst

View full text Add to dashboard Cite

show abstract

“…Tumor cell reprogramming experiments exert rather conflicting effects on malignant progression. On the one hand, reprogramming leads to a loss of oncogenicity [ 169 , 170 ] and the suppression of metastasis [ 171 , 172 , 173 ], which is associated with MET, while, on the other hand, the expression of reprogramming factors is associated with a poor disease prognosis [ 172 , 174 , 175 , 176 ]. Thus, induction of EMT using reprogramming factors and the potential of this approach as potential antitumor therapy requires further studies and a deeper understanding of the molecular mechanisms underlying the relationship between pluripotency and cell plasticity.…”

Section: Cell Plasticity and Cancer Progressionmentioning

confidence: 99%

Epithelial–mesenchymal transition: role in cancer progression and the perspectives of antitumor treatment

et al. 2020

View full text Add to dashboard Cite

About 90% of all malignant tumors are of epithelial nature. The epithelial tissue is characterized by a close interconnection between cells through cellcell interactions, as well as a tight connection with the basement membrane, which is responsible for cell polarity. These interactions strictly determine the location of epithelial cells within the body and are seemingly in conflict with the metastatic potential that many cancers possess (the main criteria for highly malignant tumors). Tumor dissemination into vital organs is one of the primary causes of death in patients with cancer. Tumor dissemination is based on the so-called epithelialmesenchymal transition (EMT), a process when epithelial cells are transformed into mesenchymal cells possessing high mobility and migration potential. More and more studies elucidating the role of the EMT in metastasis and other aspects of tumor progression are published each year, thus forming a promising field of cancer research. In this review, we examine the most recent data on the intracellular and extracellular molecular mechanisms that activate EMT and the role they play in various aspects of tumor progression, such as metastasis, apoptotic resistance, and immune evasion, aspects that have usually been attributed exclusively to cancer stem cells (CSCs). In conclusion, we provide a detailed review of the approved and promising drugs for cancer therapy that target the components of the EMT signaling pathways.

show abstract

“…As mentioned earlier, CITED2 directly or indirectly regulates expression of key stem cell transcription factors, OCT4, Nanog, Klf4 and Tbx3. These transcription factors are also known to be key players in cancer stem-like cells (112)(113)(114)(115). Therefore, it is possible that CITED2 serves a key role in cancer stem cell function.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Role of CITED2 in stem cells and cancer (Review)

Yang

2020

Oncol Lett

View full text Add to dashboard Cite

Cbp/P300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) is a transcription co-factor that interacts with several other transcription factors and co-factors, and serves critical roles in fundamental cell processes, including proliferation, apoptosis, differentiation, migration and autophagy. The interacting transcription factors or co-factors of CITED2 include LIM homeobox 2, transcription factor AP-2, SMAD2/3, peroxisome proliferator-activated receptor γ, oestrogen receptor, MYC, Nucleolin and p300/CBP, which regulate downstream gene expression, and serve important roles in the aforementioned fundamental cell processes. Emerging evidence has demonstrated that CITED2 serves an essential role in embryonic and adult tissue stem cells, including hematopoietic stem cells and tendon-derived stem/progenitor cells. Additionally, CITED2 has been reported to function in different types of cancer. Although the functions of CITED2 in different tissues vary depending on the interaction partner, altered CITED2 expression or altered interactions with transcription factors or co-factors result in alterations of fundamental cell processes, and may affect stem cell maintenance or cancer cell survival. The aim of this review is to summarize the molecular mechanisms of CITED2 function and how it serves a role in stem cells and different types of cancer based on the currently available literature.

show abstract

Co-expression of Cancer Stem Cell Markers OCT4 and NANOG Predicts Poor Prognosis in Renal Cell Carcinomas

Cited by 86 publications

References 44 publications

Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival

Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival

Epithelial–mesenchymal transition: role in cancer progression and the perspectives of antitumor treatment

Role of CITED2 in stem cells and cancer (Review)

Contact Info

Product

Resources

About